Amivantamab in Adenoid Cystic Carcinoma

Summary

The purpose of the study is to determine if treatment with amivantamab will be efficacious in patients with recurrent and metastatic adenoid cystic carcinoma.

Timeline

Start

2022-08-05

Primary completion

2026-03-02

Completion

2028-08-05

Outcome

Missed primary endpoint

paper While the primary end point of best ORR was not met in this nonrandomized clinical trial PMID 41746627 ↗

Publications

• Hanna GJ, Zamulko OY, Grover P, Adkins DR, Oppelt PJ, Romano AE, Lehn MA, Bachmann LM, Wikenheiser-Brokamp KA, Lemmon CA, Forsythe AJ, Allen CL, Pan J, Rai SN, El-Gamal D, Wise-Draper TM. Amivantamab for Recurrent or Metastatic Adenoid Cystic Carcinoma: A Phase 2 Nonrandomized Clinical Trial. JAMA Otolaryngol Head Neck Surg. 2026 Apr 1;152(4):376-383. doi: 10.1001/jamaoto.2025.5404.

Drugs

Indications